1. Scrip
  2. >>Therapy Areas

Apellis Has New Hope for Pegcetacoplan With Longer-Term Data

18-Month Results Could Vindicate Geographic Atrophy Program

 
• By Alaric DeArment

One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.

Eye
Apellis announced longer-term data for pegcetacoplan in geographic atrophy • Source: Shutterstock

Apellis Pharmaceuticals, Inc. bolstered its chances of success for its intravitreal pegcetacoplan in geographic atrophy with Phase III follow-up data that vindicated a study previously viewed as a failure.

Apellis said on 16 March that in longer-term data from the Phase III DERBY and OAKS studies, pegcetacoplan had continued...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas